Unique benefits of nanotechnology to drug delivery and diagnostics.

Nanotechnology offers many potential benefits to medical research by making pharmaceuticals more efficacious and by decreasing their adverse side-effects. Preclinical characterization of nanoparticles intended for medical applications is complicated--due to the variety of materials used, their unique surface properties and multifunctional nature. This chapter serves as an introduction to the volume, giving a broad overview of applications of nanotechnology to medicine, and describes some of the beneficial aspects of nanotechnology-based drug delivery. We define nanotechnology and provide brief descriptions of the major classes of nanomaterials used for medical applications. The following two chapters discuss scientific and regulatory hurdles involved in the use of nanotechnology in medicine. The remaining bulk of the volume provides the reader with protocols that have been tested against clinically relevant nanoparticles and describes some of the nuances of nanoparticle types and necessary controls.

[1]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Maeda,et al.  Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. , 2003, Advances in experimental medicine and biology.

[3]  R. Lockey,et al.  Nanoparticle-mediated gene delivery: state of the art , 2004, Expert opinion on biological therapy.

[4]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[6]  Anil K Patri,et al.  Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. , 2005, Advanced drug delivery reviews.

[7]  S. Sahoo,et al.  Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.

[8]  Lawrence Tamarkin,et al.  Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.

[9]  M J Hawkins,et al.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.